Literature DB >> 29404651

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

M Löbermann1, B Handorn2, A Winkelmann3, E C Reisinger4, H P Hartung5,6, U K Zettl3.   

Abstract

In June 2017 the European Court of Justice (ECJ) issued a verdict on the legal assessment of the association between hepatitis B immunization and the subsequent manifestation of multiple sclerosis (MS). This led to a high level of insecurity in the medical field as well as the normal population, especially in MS patients. The aim of this article is to briefly present the evidence-based medical facts and in particular to clearly highlight the legal aspects of the abovenamed ECJ verdict.

Entities:  

Keywords:  Burden of proof; Court verdict; Hepatitis B vaccination; Medicinal products liability; Product liability

Mesh:

Year:  2018        PMID: 29404651     DOI: 10.1007/s00115-018-0492-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  28 in total

1.  Multiple sclerosis and hepatitis B vaccine?

Authors:  A Hall; M Kane; C Roure; A Meheus
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

2.  No increase in demyelinating diseases after hepatitis B vaccination.

Authors:  F Zipp; J G Weil; K M Einhäupl
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

Review 3.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

4.  A shadow falls on hepatitis B vaccination effort.

Authors:  E Marshall
Journal:  Science       Date:  1998-07-31       Impact factor: 47.728

5.  School-based hepatitis B vaccination programme and adolescent multiple sclerosis.

Authors:  A D Sadovnick; D W Scheifele
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

6.  Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine.

Authors:  L Herroelen; J de Keyser; G Ebinger
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

7.  Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine.

Authors:  F E André
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

8.  Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.

Authors:  Annette Langer-Gould; Lei Qian; Sara Y Tartof; Sonu M Brara; Steve J Jacobsen; Brandon E Beaber; Lina S Sy; Chun Chao; Rulin Hechter; Hung Fu Tseng
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

Review 9.  Vaccines and multiple sclerosis: a systematic review.

Authors:  Mia Topsøe Mailand; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2016-09-07       Impact factor: 6.682

Review 10.  Non-specific immunological effects of selected routine childhood immunisations: systematic review.

Authors:  Rama Kandasamy; Merryn Voysey; Fiona McQuaid; Karlijn de Nie; Rebecca Ryan; Olivia Orr; Ulrike Uhlig; Charles Sande; Daniel O'Connor; Andrew J Pollard
Journal:  BMJ       Date:  2016-10-13
View more
  2 in total

Review 1.  [Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Authors:  Alexander Winkelmann; Micha Löbermann; Uwe K Zettl
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

Review 2.  [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Authors:  Tobias Monschein; Tobias Zrzavy; Micha Löbermann; Alexander Winkelmann; Thomas Berger; Paulus Rommer; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nervenarzt       Date:  2021-07-07       Impact factor: 1.297

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.